Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 49.88 |
---|---|
High | 55.48 |
Low | 49.88 |
Bid | 55.36 |
Offer | 55.82 |
Previous close | 50.74 |
Average volume | 10.10 |
---|---|
Shares outstanding | 104.78m |
Free float | 92.70m |
P/E (TTM) | 46.94 |
Market cap | 6.24bn USD |
EPS (TTM) | 1.27 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 18:30 GMT.
More ▼
- Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
- Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
- Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
- Corcept Completes Enrollment in Phase 4 CATALYST Trial
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
- Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
More ▼